Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-O21.1
- Development stage
- Unknown
- Lead developer
- Lamassu Pharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
AD-O21.1 is a recombinant fusion protein variant of TRAIL (TNF-related apoptosis-inducing ligand), also known as Apo2L, developed by Adamed Pharma (including its subsidiary Polfa Pabianice). The drug is designed to selectively induce apoptosis in cancer cells by acting as an agonist for the death receptors DR4 (TNFRSF10A) and DR5 (TNFRSF10B). Unlike first-generation recombinant TRAIL molecules, AD-O21.1 is a modified fusion variant engineered to enhance stability, improve pharmacokinetic properties, and increase pro-apoptotic activity within the tumor microenvironment. It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, where it aims to overcome the therapeutic limitations observed with native TRAIL proteins.
- Other names
- recombinant TRAIL/Apo2L proteinrecombinant fusion variant of TRAIL/Apo2L proteinTRAIL/Apo2L fusion protein
02
Targets
TNFRSF10B (DR5)TNFRSF10A (Death receptor 4)
Beyond the preview
Go deeper on AD-O21.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-O21.1.